Given its approval for MDS, more VEXAS patients with a co-diagnosis of MDS receive Azacitidine, with some studies indicating that patients who respond to the treatment often have concurrent mutations in DNMT3A [95]. The gene discussed is DNMT3A; the disease is myelodysplastic syndrome.